|
News
2008 – 2007 – 2006 – 2005
December 22, 2005
Amorfix Achieves First Technical Milestone and Begins Assay Validation with Human vCJD Blood Samples
Amorfix Life Sciences Ltd. (TSX-V - AMF) announced today that it has successfully completed its first research and development milestone to develop a test for the detection of prions in blood from laboratory animals. More
November 25, 2005
Amorfix Reports Second Quarter Results For Fiscal Year 2006
More
October 19, 2005
Amorfix To Present Its Epitope Protection Technology At The International Prion 2005 Conference In Germany
Amorfix Life Sciences Ltd. (TSXV: AMF) announced today that it is presenting for the first time its Epitope Protection technology at the German TSE Research Platform and the European Network of Excellence NeuroPrion international conference, Prion 2005, to be held in Düsseldorf, Germany, from October 19-21, 2005. More
October 3, 2005
Amorfix Life Sciences Ltd. To Begin Trading
Amorfix Life Sciences Ltd. (TSX-V – AMF) is pleased to announce that the TSX Venture Exchange has granted final acceptance of its listing application and that trading will commence today under the symbol “AMF”. More
September 21, 2005
Luxor/Amorfix Complete Amalgamation And Financing
Luxor Developments Inc. is pleased to announce that today it completed an amalgamation with Amorfix Life Sciences Ltd. The amalgamated company will continue under the Amorfix name. Having previously received conditional TSX-V approval for this amalgamation and related transactions (see news release of August 31, 2005), the amalgamated company hopes to begin trading under the Amorfix name and new trade symbol, AMF, sometime around the beginning of October. Prior to returning to trade, the amalgamated company must complete its filings with the TSX-V as required in order to satisfy the conditions in the TSX-V's conditional approval letter. Once the company completes this filing and confirms with the TSX-V the date it will return to trade, it will issue a news release to confirm same. More
August 31, 2005
Luxor And Amorfix Announce Mailing Of Circular
Luxor Developments Inc. (“Luxor”) and Amorfix Life Sciences Ltd. (“Amorfix”) are pleased to announce that they have mailed the Joint Information Circular for Luxor’s Annual and Special Meeting and Amorfix’s Annual and Special Meeting to approve the previously announced amalgamation of the two companies. Both meetings will be held on September 20, 2005. More
June 21, 2005
Luxor Developments Proceeding with Proposed Acquisition of Amorfix Life Sciences
Luxor Developments Inc. ("Luxor") is pleased to announce that it has entered into an “arms length” amalgamation agreement dated June 7, 2005 (the "Amalgamation Agreement") with Amorfix Life Sciences Ltd. ("Amorfix"), a private biotechnology company. Subject to acceptance by TSX Venture Exchange (the "Exchange"), the completion of the amalgamation will constitute Luxor’s qualifying transaction ("QT") under Exchange Policy 2.4. More
|
